Autolus Therapeutics (AUTL) has issued an announcement.
Autolus Therapeutics plc recently announced promising updates on their pivotal FELIX study of obecabtagene autoleucel, a potential treatment for relapsed/refractory adult B-cell Acute Lymphoblastic Leukemia, at the ASCO Annual Meeting. Following this, they conducted a conference call and webcast to delve into the data, engaging the investment community with insights into the study’s longer-term outcomes and additional analyses. The presented information, though not filed under SEC regulations, is a significant stride in the company’s communication with its stakeholders.
For an in-depth examination of AUTL stock, go to TipRanks’ Stock Analysis page.
